GHG names two new senior vice presidents

Grey Healthcare Group named Beverly Beaudoin senior vice president, general manager of Avenue Grey. Beaudoin was director, DTP/DTC for Lowe Bozell McAdams, where she was responsible for growing the DTP/DTC business. In addition to working on PapSure, an OB/GYN device, and the OTC launch of Metrika's A1cNOW device for diabetes, she also oversaw the successful DTP component of the Xolair launch, the first-in-class biologic for the treatment of moderate to severe persistent allergic asthma. Prior, Beaudoin was president and chief operating officer of Bigfoot Interactive, a direct e-CRM company.
Steve Corwin was named senior vice president, general manager of Acute and Specialty Care Brands. He was a principal at DeNova Healthcare Communications, where he developed marketing, business development, and communications programs for pharmaceutical and biotech companies. He also developed medical center-based education programs for professional and patient audiences. Before that, he was senior vice president at McCann Erickson Healthcare Worldwide, Regan Campbell Ward, focusing on anti-infective, cardiovascular, and oncology brands.
"Grey Healthcare Group continues to enjoy double-digit growth, which is why we are able to attract such great talent," said Jane Parker, president, Grey Healthcare Group Advertising Worldwide. "We know that Beverly and Steve will help make GHG's DTC/DTP and oncology, acute and specialty care brands even stronger around the world."

You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.